Loading...
Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients with Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-existing Liver and/or Renal Dysfunction
BACKGROUND: The safety and efficacy of frontline nilotinib and dasatinib in newly diagnosed chronic-phase chronic myelogenous leukemia (CML-CP) patients with pre-existing liver and/or renal dysfunction are unknown. PATIENTS AND METHODS: We analyzed adverse event rates, response rates, and survival r...
Na minha lista:
| Udgivet i: | Clin Lymphoma Myeloma Leuk |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2015
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4769134/ https://ncbi.nlm.nih.gov/pubmed/26796981 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2015.12.003 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|